Table 2.

Detailed clinical and molecular characteristics of the six patients with MSI-H lung cancer

NO	Sex	Age	Smoking	Pathology diagnosis	Stage	MSI status detection	Driver Gene	KRAS mutation status	TP53 mutation status	Other concomitant gene mutation	Metastasis	PD-L1 TPS (%)	TMB (mut/Mb)	Tissue sample assayed	Treatment setting	Treatment regimen	Best response	PFS (months)
M2	F	54	Never	LUAD	IV	NGS	EGFR mutation	WT	WT	WT	Lung, bone	70	Unknown	Primary tumor	First-line	Chemo+pembrolizumab	SD	4.0
M10	M	48	Former	LUAD	IV	NGS and IHC	WT	WT	WT	MLH, PIK3R1, PRKDC, PTEN, TSC1	Pleura	0	18.3	Primary tumor	First-line	Chemo+pembrolizumab	CR	44.5 +
M18	F	47	Never	LUAD	IV	NGS	BRAF mutation	WT	WT	WT	Lung, brain	0	4.18	Lymph node	First-line	Chemo+pembrolizumab	PR	11.3
M24	M	58	Never	LUAD	IV	NGS	WT	WT	Mutated	CDKN2A	Bone	50	26.12	Primary tumor	First-line	Pembrolizumab	PR	42.1 +
M25	M	68	Former	LUSC	IV	NGS	WT	WT	WT	PIK3CA	None	Unknown	Unknown	Primary tumor	First-line	Pembrolizumab	PR	10.0
M34	F	48	Never	LUSC	III	NGS	WT	WT	WT	PTEN	None	100	Unknown	Primary tumor	First-line	Chemo+pembrolizumab	CR	7.7 +

PFS values with plus  (+) symbols indicate that the patient was still receiving the treatment regimen as of data cutoff date

Chemo Chemotherapy; CR Complete response; F Female, LUAD Lung adenocarcinoma; LUSC Lung squamous cell carcinoma; M Male, PD-L1 TPS Programmed cell death-ligand 1 tumor proportion score; PFS Progression free survival; PR Partial response; SD Stable disease; WT Wild type